Rubens Reimão
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rubens Reimão has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Sueli Rossini
S. Rossini, PhD, Division of Clinical Neurology, Sleep Medicine Advanced Research Group, Clinicas Hospital of the University of São Paulo, University of São Paulo School of Medicine, São Paulo, Brazil
11 shared publications- José Carlos Souza
Universidade Estadual de Mato Grosso do Sul
5 shared publications - Isabelle Arnulf
Sleep Clinic, Pitie-Salpetriere Hospital, DMU APPROCHES, Assistance Publique-Hôpitaux de Paris- Sorbonne Université, Paris, France; Paris Brain Institute (ICM), DreamTeam, Paris, France
4 shared publications - Jian-Sheng Lin
Lyon Neuroscience Research Center, Waking team
4 shared publications José Carlos Souza
Campinas State University, Campinas, SP, Brazil
4 shared publicationsAude Raoux
Integrative Physiology of Brain Arousal System CRNL INSERM‐U1028 CNRS UMR5292 University Lyon1 Lyon France
3 shared publications
Latest Publications
- Open Access
- 1 December 2015
- Published by Georg Thieme Verlag KG in Sleep Science
- Vol. 8 (4) , 205-206
FATORES PSICOSSOCIAIS RELACIONADOS AO INÍCIO DOS SINTOMAS DE NARCOLEPSIA
- 1 December 2015
- Published by Georg Thieme Verlag KG in Sleep Science
- Vol. 8 (4) , 205-206
Open AccessFATORES PSICOSSOCIAIS RELACIONADOS AO INÍCIO DOS SINTOMAS DE NARCOLEPSIA
- 16 July 2014
- Published by Taylor & Francis in Cranio®
- Vol. 33 (2) , 122-128
Sleep quality and facial pain in fibromyalgia syndrome
This study aims to evaluate the sleep conditions in fibromyalgia syndrome and the influence of the temporomandibular disorders (TMDs) and fibromyalgia association in self-reported sleep quality. Forty female patients with fibromyalgia (FMS) were compared with 40 healthy women [control group (CG)]. Three questionnaires were used (i.e. RDC/TMD to diagnose TMD and to determine pain intensity and disability and Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) to assess sleep conditions). Statistical analyses were performed using the Wilcoxon-Mann-Whitney test to ordinal variables, Student's t-test to obtain the quantitative total scores of PSQI and chronic pain classification, Spearman's rho to determine the correlation between facial pain and quality sleep, and Fisher's exact test for other variables. A moderate correlation between facial pain intensity and low sleep quality was found (rho = 0·56; P0·05). Excessive daytime sleepiness was more prevalent in FMS (37·5%; P<0·0001) besides having the worst sleep quality (PSQI = 12·72) compared with CG (PSQI = 4·62). Fibromyalgia patients experience intense facial pain in addition to poor sleep and high disabilities. TMD and FMS association do not appear to worsen this condition; however, facial pain intensity was correlated with low sleep quality.
- 16 July 2014
- Published by Taylor & Francis in Cranio®
- Vol. 33 (2) , 122-128
Sleep quality and facial pain in fibromyalgia syndrome
This study aims to evaluate the sleep conditions in fibromyalgia syndrome and the influence of the temporomandibular disorders (TMDs) and fibromyalgia association in self-reported sleep quality. Forty female patients with fibromyalgia (FMS) were compared with 40 healthy women [control group (CG)]. Three questionnaires were used (i.e. RDC/TMD to diagnose TMD and to determine pain intensity and disability and Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) to assess sleep conditions). Statistical analyses were performed using the Wilcoxon-Mann-Whitney test to ordinal variables, Student's t-test to obtain the quantitative total scores of PSQI and chronic pain classification, Spearman's rho to determine the correlation between facial pain and quality sleep, and Fisher's exact test for other variables. A moderate correlation between facial pain intensity and low sleep quality was found (rho = 0·56; P0·05). Excessive daytime sleepiness was more prevalent in FMS (37·5%; P<0·0001) besides having the worst sleep quality (PSQI = 12·72) compared with CG (PSQI = 4·62). Fibromyalgia patients experience intense facial pain in addition to poor sleep and high disabilities. TMD and FMS association do not appear to worsen this condition; however, facial pain intensity was correlated with low sleep quality.
- 12 June 2014
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 20 (8) , 763-771
Quality of Life in Children with Narcolepsy
Summary: Aims: To evaluate the health‐related quality of life (HRQL) and its correlates in children and adolescents with narcolepsy.Methods: We compared the clinical characteristics of control subjects and patients with primary narcolepsy from data collected at the National Reference Centers for Narcolepsy.Results: The cohort included 69 control subjects (29 boys) and 117 patients (65 boys; 59 de novo patients). Cataplexy was present in 81% and DQB1*0602 was positive in 91%. The control children were older (13.5 ± 3.2 vs. 11.6 ± 3.1 years, P < 0.001) and less obese (1.4% vs. 60%, P < 0.001). Twenty‐five percent of the patients and 15.6% of the control subjects had clinically significant depressive feelings on Children's Depression Inventory (CDI ≥ 16) (NS). Fifty‐three narcoleptic and 43 control adolescents, 31 narcoleptic children and 23 control children filled out the HRQL questionnaires as well as 83 parents of patients and 60 parents of control subjects. Narcolepsy seriously impacts HRQL in terms of vitality, physical well‐being, relations with friends and leisure activities, especially in adolescents. Depression was the factor that most affected HRQL in both narcoleptic and control subjects. For the control subjects and the narcoleptic patients, when the CDI score was entered into the multivariable regression model adjusted for gender and age, no other continuous independent variable could significantly increase the likelihood of the model. When the CDI score increased by 1, the mean HRQL score decreased by 1.7 for narcoleptic patients and 1.5 for control subjects. Apnea–hypopnoea index, diagnosis delay, disease duration, obesity, the presence of cataplexy or treatment had no effects on HRQL.Conclusions: Narcoleptic children and adolescents were at high risk for poor HRQL. Depressive symptoms had a major impact on HRQL. We recommend a more thorough assessment and management of psychological health in this population.
- 12 June 2014
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 20 (8) , 763-771
Quality of Life in Children with Narcolepsy
Summary: Aims: To evaluate the health‐related quality of life (HRQL) and its correlates in children and adolescents with narcolepsy.Methods: We compared the clinical characteristics of control subjects and patients with primary narcolepsy from data collected at the National Reference Centers for Narcolepsy.Results: The cohort included 69 control subjects (29 boys) and 117 patients (65 boys; 59 de novo patients). Cataplexy was present in 81% and DQB1*0602 was positive in 91%. The control children were older (13.5 ± 3.2 vs. 11.6 ± 3.1 years, P < 0.001) and less obese (1.4% vs. 60%, P < 0.001). Twenty‐five percent of the patients and 15.6% of the control subjects had clinically significant depressive feelings on Children's Depression Inventory (CDI ≥ 16) (NS). Fifty‐three narcoleptic and 43 control adolescents, 31 narcoleptic children and 23 control children filled out the HRQL questionnaires as well as 83 parents of patients and 60 parents of control subjects. Narcolepsy seriously impacts HRQL in terms of vitality, physical well‐being, relations with friends and leisure activities, especially in adolescents. Depression was the factor that most affected HRQL in both narcoleptic and control subjects. For the control subjects and the narcoleptic patients, when the CDI score was entered into the multivariable regression model adjusted for gender and age, no other continuous independent variable could significantly increase the likelihood of the model. When the CDI score increased by 1, the mean HRQL score decreased by 1.7 for narcoleptic patients and 1.5 for control subjects. Apnea–hypopnoea index, diagnosis delay, disease duration, obesity, the presence of cataplexy or treatment had no effects on HRQL.Conclusions: Narcoleptic children and adolescents were at high risk for poor HRQL. Depressive symptoms had a major impact on HRQL. We recommend a more thorough assessment and management of psychological health in this population.
- 1 March 2014
- Published by Elsevier in Sleep Medicine
- Vol. 15 (3) , 309-314
Depressive feelings in children with narcolepsy
- 1 March 2014
- Published by Elsevier in Sleep Medicine
- Vol. 15 (3) , 309-314
Depressive feelings in children with narcolepsy
- Open Access
- 1 August 2013
- Published by Oxford University Press (OUP) in Physical Therapy
- Vol. 93 (8) , 1092-1101
Facial Pain Associated With Fibromyalgia Can Be Marked by Abnormal Neuromuscular Control: A Cross-Sectional Study
Background: Temporomandibular disorder (TMD) development in fibromyalgia syndrome (FMS) is not yet fully understood, but altered neuromuscular control in FMS may play a role in triggering TMD. Objective: The purpose of this study was to verify the association between neuromuscular control and chronic facial pain in groups of patients with FMS and TMD. Design: A cross-sectional study was conducted. Methods: This study involved an analysis of facial pain and electromyographic activity of the masticatory muscles in patients with FMS (n=27) and TMD (n=28). All participants were evaluated according to Research Diagnostic Criteria for Temporomandibular Disorders and surface electromyography (SEMG). Myoelectric signal calculations were performed using the root mean square and median frequency of signals. Results: The data revealed premature interruption of masticatory muscle contraction in both patient groups, but a significant correlation also was found between higher median frequency values and increased facial pain. This correlation probably was related to FMS because it was not found in patients with TMD only. Facial pain and increased SEMG activity during mandibular rest also were positively correlated. Limitations: Temporal conclusions cannot be drawn from the study. Also, the study lacked a comparison group of patients with FMS without TMD as well as a control group of individuals who were healthy. Conclusions: Altered neuromuscular control in masticatory muscles may be correlated with perceived facial pain in patients with FMS.
- 1 August 2013
- Published by Oxford University Press (OUP) in Physical Therapy
- Vol. 93 (8) , 1092-1101
Open AccessFacial Pain Associated With Fibromyalgia Can Be Marked by Abnormal Neuromuscular Control: A Cross-Sectional Study
Background: Temporomandibular disorder (TMD) development in fibromyalgia syndrome (FMS) is not yet fully understood, but altered neuromuscular control in FMS may play a role in triggering TMD. Objective: The purpose of this study was to verify the association between neuromuscular control and chronic facial pain in groups of patients with FMS and TMD. Design: A cross-sectional study was conducted. Methods: This study involved an analysis of facial pain and electromyographic activity of the masticatory muscles in patients with FMS (n=27) and TMD (n=28). All participants were evaluated according to Research Diagnostic Criteria for Temporomandibular Disorders and surface electromyography (SEMG). Myoelectric signal calculations were performed using the root mean square and median frequency of signals. Results: The data revealed premature interruption of masticatory muscle contraction in both patient groups, but a significant correlation also was found between higher median frequency values and increased facial pain. This correlation probably was related to FMS because it was not found in patients with TMD only. Facial pain and increased SEMG activity during mandibular rest also were positively correlated. Limitations: Temporal conclusions cannot be drawn from the study. Also, the study lacked a comparison group of patients with FMS without TMD as well as a control group of individuals who were healthy. Conclusions: Altered neuromuscular control in masticatory muscles may be correlated with perceived facial pain in patients with FMS.
- 10 April 2013
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 19 (7) , 521-528
Impact of Obesity in Children with Narcolepsy
Summary: Aims: To evaluate the impact of obesity on clinical and sleep characteristics in a population of narcoleptic children.Methods: Data from the children diagnosed with idiopathic narcolepsy in the National Reference Centers for Narcolepsy were collected between 2008 and 2011. Clinical and electrophysiological characteristics were compared between obese (body mass index [BMI] greater than P97) and nonobese children.Results: The 117 children (65 boys, 59 de novo patients) had a mean age of 11.6 ± 3.1 years on diagnosis. Cataplexy was present in 81%, DQB1*0602 in 91%. Mean BMI was 23.2 ± 5.2 kg/m2 and BMI z‐score was 2.9 ± 2.6. Obesity was found in 60% with a similar prevalence in treated versus de novo patients and in patients with and without cataplexy. Sleepiness and cataplexy started earlier in obese children. Obese narcoleptic children had lower sleep efficiency, higher apnea hypopnea index and respiratory arousals index (RAI) than nonobese children. BMI z‐score was positively correlated with RAI. Obese children were more tired and missed more often school than nonobese children.Conclusion: Obesity affects more than 50% of narcoleptic children, mostly younger at disease onset, and has a deleterious impact on sleep quality as well as on school attendance.
- 10 April 2013
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 19 (7) , 521-528
Impact of Obesity in Children with Narcolepsy
Summary: Aims: To evaluate the impact of obesity on clinical and sleep characteristics in a population of narcoleptic children.Methods: Data from the children diagnosed with idiopathic narcolepsy in the National Reference Centers for Narcolepsy were collected between 2008 and 2011. Clinical and electrophysiological characteristics were compared between obese (body mass index [BMI] greater than P97) and nonobese children.Results: The 117 children (65 boys, 59 de novo patients) had a mean age of 11.6 ± 3.1 years on diagnosis. Cataplexy was present in 81%, DQB1*0602 in 91%. Mean BMI was 23.2 ± 5.2 kg/m2 and BMI z‐score was 2.9 ± 2.6. Obesity was found in 60% with a similar prevalence in treated versus de novo patients and in patients with and without cataplexy. Sleepiness and cataplexy started earlier in obese children. Obese narcoleptic children had lower sleep efficiency, higher apnea hypopnea index and respiratory arousals index (RAI) than nonobese children. BMI z‐score was positively correlated with RAI. Obese children were more tired and missed more often school than nonobese children.Conclusion: Obesity affects more than 50% of narcoleptic children, mostly younger at disease onset, and has a deleterious impact on sleep quality as well as on school attendance.
- Open Access
- 11 January 2013
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 71 (2) , 78-82
Quality of life and sleep in obese adolescents
Obesity and sleep disorders in adolescence are strongly associated, and they impact both on the health and on quality of life (QL) in this age group. OBJECTIVE: To comparatively assess QL and sleep in obese and eutrophic adolescents, who are older than ten years of age. METHODS: Cross-sectional study including obese adolescents. This analysis was carried out between August 2009 and August 2010. The Control (eutrophic) Group comprised schoolchildren recruited from State schools in the city of Americana, in São Paulo State, Brazil. Instruments applied included a standardized questionnaire, the Sleep Behavior Questionnaire (SBQ), and the Pediatric QL Inventory (PedsQL TM 4.0). RESULTS: The obese adolescents had poorer QL on physical (p<0.001), emotional (p=0.03), and social (p=0.002) functioning domains. A difference in mean psychosocial functioning was found between the groups (p=0.009) with obese subjects having a mean score of 69.5 (±16.0) and in eutrophic individuals of 76.2 (±16.7). A greater number of sleep problems was evident in the Obese Group (p=0.03). Conclusions: The obese adolescents had an impaired QL and a higher frequency of sleep problems compared to the eutrophic subjects.
- 11 January 2013
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 71 (2) , 78-82
Open AccessQuality of life and sleep in obese adolescents
Obesity and sleep disorders in adolescence are strongly associated, and they impact both on the health and on quality of life (QL) in this age group. OBJECTIVE: To comparatively assess QL and sleep in obese and eutrophic adolescents, who are older than ten years of age. METHODS: Cross-sectional study including obese adolescents. This analysis was carried out between August 2009 and August 2010. The Control (eutrophic) Group comprised schoolchildren recruited from State schools in the city of Americana, in São Paulo State, Brazil. Instruments applied included a standardized questionnaire, the Sleep Behavior Questionnaire (SBQ), and the Pediatric QL Inventory (PedsQL TM 4.0). RESULTS: The obese adolescents had poorer QL on physical (p<0.001), emotional (p=0.03), and social (p=0.002) functioning domains. A difference in mean psychosocial functioning was found between the groups (p=0.009) with obese subjects having a mean score of 69.5 (±16.0) and in eutrophic individuals of 76.2 (±16.7). A greater number of sleep problems was evident in the Obese Group (p=0.03). Conclusions: The obese adolescents had an impaired QL and a higher frequency of sleep problems compared to the eutrophic subjects.
- Open Access
- 31 October 2012
- Published by Editora Cubo in Brazilian Dental Science
- Vol. 15 (2) , 27-34
Temporomandibular disorders in fibromyalgia: a critical view
A disfunção temporomandibular (DTM) e a fibromialgia (FM) são sindromes musculo-esqueléticas que parecerem estar associadas. Vários estudos na literatura relatam sinais e sintomas da DTM em pacientes com FM. O objetivo deste trabalho foi analisar a literatura recente quanto a associação clínica entre fibromialgia e as disfunções temporomandibulares. Apesar destes distúrbios possuírem etiologias diferente, o mecanismo de modulação de dor são semelhantes. Muitas pesquisas desenvolvidas nessa área buscam elucidar esta questão ainda pouco compreendida. Mas sugere-se que estas síndromes são caracterizadas por uma diminuição no limiar de dor e na capacidade de atenuação de sistemas descendente de modulação da dor. Além disso, há um certo grau de comorbidade entre estas duas patologias, que compartilham muitas características clínicas. Muitos pacientes com FM apresentam vários sinais e sintomas de DTM, entretando, uma pequena quantidade de indivíduos com DTM recebem um diagnóstico de FM. Portanto, é importante uma avaliação precisa e adequada do sistema estomatognático em pacientes com fibromialgia englobando o diagnóstico de disfunção temporomandibular na intervenção terapêutica.
- 31 October 2012
- Published by Editora Cubo in Brazilian Dental Science
- Vol. 15 (2) , 27-34
Open AccessTemporomandibular disorders in fibromyalgia: a critical view
A disfunção temporomandibular (DTM) e a fibromialgia (FM) são sindromes musculo-esqueléticas que parecerem estar associadas. Vários estudos na literatura relatam sinais e sintomas da DTM em pacientes com FM. O objetivo deste trabalho foi analisar a literatura recente quanto a associação clínica entre fibromialgia e as disfunções temporomandibulares. Apesar destes distúrbios possuírem etiologias diferente, o mecanismo de modulação de dor são semelhantes. Muitas pesquisas desenvolvidas nessa área buscam elucidar esta questão ainda pouco compreendida. Mas sugere-se que estas síndromes são caracterizadas por uma diminuição no limiar de dor e na capacidade de atenuação de sistemas descendente de modulação da dor. Além disso, há um certo grau de comorbidade entre estas duas patologias, que compartilham muitas características clínicas. Muitos pacientes com FM apresentam vários sinais e sintomas de DTM, entretando, uma pequena quantidade de indivíduos com DTM recebem um diagnóstico de FM. Portanto, é importante uma avaliação precisa e adequada do sistema estomatognático em pacientes com fibromialgia englobando o diagnóstico de disfunção temporomandibular na intervenção terapêutica.
- Open Access
- 1 June 2012
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 70 (6) , 422-427
Quality of sleep and quality of life in adolescents infected with human immunodeficiency virus
OBJECTIVES: To assess sleep characteristics of adolescents infected by HIV, and to ascertain whether psychosocial aspects are associated to the quality of sleep. METHODS: A cross-sectional study assessing 102 HIV-infected adolescents of both genders, aged between 10 and 20 years-old and 120 Controls. Data collection was performed by applying the Sleep Disturbance Scale for Children, the Epworth Sleepiness Scale, and the Pediatric Quality of Life Inventory. RESULTS: A sleep disturbance prevalence of 77.4% was found in patients, and a 75% prevalence in controls, and there was correlation between quality of sleep and of life. HIV-infected adolescents scored higher for sleep breathing disorders and had higher prevalence of excessive daytime sleepiness. CONCLUSIONS: HIV-infected adolescents had similar quality of sleep compared to healthy adolescents. This may be explained by the steady improvements in daily living as a result of successful anti-retroviral therapy, and by the vulnerability that affects Brazilian adolescents living in major urban centers.
- 1 June 2012
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 70 (6) , 422-427
Open AccessQuality of sleep and quality of life in adolescents infected with human immunodeficiency virus
OBJECTIVES: To assess sleep characteristics of adolescents infected by HIV, and to ascertain whether psychosocial aspects are associated to the quality of sleep. METHODS: A cross-sectional study assessing 102 HIV-infected adolescents of both genders, aged between 10 and 20 years-old and 120 Controls. Data collection was performed by applying the Sleep Disturbance Scale for Children, the Epworth Sleepiness Scale, and the Pediatric Quality of Life Inventory. RESULTS: A sleep disturbance prevalence of 77.4% was found in patients, and a 75% prevalence in controls, and there was correlation between quality of sleep and of life. HIV-infected adolescents scored higher for sleep breathing disorders and had higher prevalence of excessive daytime sleepiness. CONCLUSIONS: HIV-infected adolescents had similar quality of sleep compared to healthy adolescents. This may be explained by the steady improvements in daily living as a result of successful anti-retroviral therapy, and by the vulnerability that affects Brazilian adolescents living in major urban centers.
- 1 March 2012
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 35 (2) , 55-60
Pitolisant, an Inverse Agonist of the Histamine H3 Receptor
Narcolepsy is a rare disabling sleep disorder characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone). Drugs such as pitolisant, which block histamine H3 autoreceptors, constitute a newly identified class of stimulants because they increase brain histamine and enhance wakefulness in animal and human adult narcolepsy. We report our experience with the off-label use of pitolisant in 4 teenagers with narcolepsy/cataplexy with severe daytime sleepiness, refractory to available treatments (modafinil, methylphenidate, mazindol, sodium oxybate, and D-amphetamine). All teenagers developed their disease during childhood (11.3 ± 2.4 years; 50% boys) and were 17.3 ± 0.8 years old at the time of pitolisant therapy. Pitolisant treatment was increased from 10 to 30 mg (n = 1) and 40 mg (n = 3). The adapted Epworth Sleepiness Score decreased from 14.3 ± 1.1 to 9.5 ± 2.9 (P = 0.03) with pitolisant alone to 7 ± 3.4 when combined with mazindol (n = 1), methylphenidate (n = 1), or sodium oxybate plus modafinil (n = 1). Mean sleep onset latency increased from 31 ± 14 minutes to 36 ± 8 minutes (P = 0.21) on the maintenance of wakefulness test. The severity and frequency of cataplexy were slightly improved. Adverse effects were minor (insomnia, headache, hot flushes, leg pain, and hallucinations) and transitory, except for insomnia, which persisted in 2 teenagers. The benefit was maintained after a mean of 13 months. Pitolisant could constitute an acceptable alternative for the treatment of refractory sleepiness in teenagers with narcolepsy.
- 1 March 2012
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 35 (2) , 55-60
Pitolisant, an Inverse Agonist of the Histamine H3 Receptor
Narcolepsy is a rare disabling sleep disorder characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone). Drugs such as pitolisant, which block histamine H3 autoreceptors, constitute a newly identified class of stimulants because they increase brain histamine and enhance wakefulness in animal and human adult narcolepsy. We report our experience with the off-label use of pitolisant in 4 teenagers with narcolepsy/cataplexy with severe daytime sleepiness, refractory to available treatments (modafinil, methylphenidate, mazindol, sodium oxybate, and D-amphetamine). All teenagers developed their disease during childhood (11.3 ± 2.4 years; 50% boys) and were 17.3 ± 0.8 years old at the time of pitolisant therapy. Pitolisant treatment was increased from 10 to 30 mg (n = 1) and 40 mg (n = 3). The adapted Epworth Sleepiness Score decreased from 14.3 ± 1.1 to 9.5 ± 2.9 (P = 0.03) with pitolisant alone to 7 ± 3.4 when combined with mazindol (n = 1), methylphenidate (n = 1), or sodium oxybate plus modafinil (n = 1). Mean sleep onset latency increased from 31 ± 14 minutes to 36 ± 8 minutes (P = 0.21) on the maintenance of wakefulness test. The severity and frequency of cataplexy were slightly improved. Adverse effects were minor (insomnia, headache, hot flushes, leg pain, and hallucinations) and transitory, except for insomnia, which persisted in 2 teenagers. The benefit was maintained after a mean of 13 months. Pitolisant could constitute an acceptable alternative for the treatment of refractory sleepiness in teenagers with narcolepsy.